Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Simoens, Cindy ^a   Lardon, Filip ^a   Pauwels, Bea ^a   De Pooter, Christel M J ^b   Lambrechts, Hilde A J ^a   Pattyn, Greet G O ^a   Breillout, Fabienne ^c   Vermorken, Jan B ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE; VINFLUNINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; RADIOSENSITIZING AGENT; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; RADIOSENSITIZATION; STATISTICAL SIGNIFICANCE; TONGUE CARCINOMA; TUMOR CELL LINE; BLADDER TUMOR; BREAST TUMOR; CARCINOMA; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GAMMA RADIATION; LUNG TUMOR; MICROTUBULE; PATHOLOGY; RADIATION EXPOSURE; STRUCTURE ACTIVITY RELATION; TONGUE TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA RAYS; HUMANS; LUNG NEOPLASMS; MICROTUBULES; MOLECULAR STRUCTURE; RADIATION-SENSITIZING AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TONGUE NEOPLASMS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 42449114880     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-65     Document Type: Article

References (47)

1. Wargin WA Lucas VS The clinical pharmacokinetics of vinorelbine (Navelbine) Semin Oncol 1994, 21:21-27. 7973765
2. Jordan MA Thrower D Wilson L Mechanism of inhibition by Vinca alkaloids Cancer Res 1991, 51:2212-2222. 2009540
3. Wilson L Panda D Jordan MA Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators Cell Struct Funct 1999, 24:329-335. 10.1247/csf.24.329 15216890
4. Binet S Chaineau E Fellous A Lataste H Krikorian A Couzinier JP Meininger V Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules Int J Cancer 1990, 46:262-266. 10.1002/ijc.2910460220 2200754
5. Ngan VK Bellman K Panda D Hill BT Jordan MA Wilson L Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules Cancer Res 2000, 60:5045-5051. 11016627
6. Ngan VK Bellman K Hill BT Wilson L Jordan MA Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine Mol Pharmacol 2001, 60:225-232. 11408618
7. Okouneva T Hill BT Wilson L Jordan MA The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics Mol Cancer Ther 2003, 2:427-436. 12748304
8. Aapro MS Harper P Johnson SA Vermorken JB Developments in cytotoxic chemotherapy: Advances in treatment utilising vinorelbine Crit Rev Oncol Hematol 2001, 40:251-263. 10.1016/S1040-8428(01)00167-6 11738948
9. Depierre A Lemarie E Dabouis G Garnier G Jacoulet P Dalphin JC A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer Am J Clin Oncol 1991, 14:115-119. 10.1097/ 00000421-199104000-00004 1851385
10. Mano M Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy Cancer Treat Rev 2006, 32:106-118. 10.1016/j.ctrv.2005.12.008 16473470
11. Bennouna J Breton JL Tourani JM Ottensmeier C O'Brien M Kosmidis P Huat TE Pinel MC Colin C Douillard JY Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: Results of a phase II study Br J Cancer 2006, 94:1383-1388. 10.1038/sj.bjc.6603106 16641911
12. Bennouna J Campone M Delord JP Pinel MC Vinflunine: A novel antitubulin agent in solid malignancies Expert Opin Investig Drugs 2005, 14:1259-1267. 10.1517/13543784.14.10.1259 16185168
13. Culine S Theodore C De Santis M Bui B Demkow T Lorenz J Rolland F Delgado FM Longerey B James N A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Br J Cancer 2006, 94:1395-1401. 10.1038/sj.bjc.6603118 16622447
14. Kruczynski A Barret JM Etievant C Colpaert F Fahy J Hill BT Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid Biochem Pharmacol 1998, 55:635-648. 10.1016/ S0006-2952(97)00505-4 9515574
15. Kruczynski A Colpaert F Tarayre JP Mouillard P Fahy J Hill BT Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid Cancer Chemother Pharmacol 1998, 41:437-447. 10.1007/s002800050764 9554586
16. Hill BT Fiebig HH Waud WR Poupon MF Colpaert F Kruczynski A Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine in a panel of human tumour xenografts Eur J Cancer 1999, 35:512-520. 10.1016/S0959-8049(98)00416-X 10448309
17. Lobert S Ingram JW Hill BT Correia JJ A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity Mol Pharmacol 1998, 53:908-915. 9584218
18. Lobert S Fahy J Hill BT Duflos A Etievant C Correia JJ Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line Biochemistry 2000, 39:12053-12062. 10.1021/bi001038r 11009620
19. Fabre C Czaplicki J Wright M Hill B Barret JM Fahy J Milon A Differential binding to the alpha/beta-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses Biochem Pharmacol 2002, 64:733-740. 10.1016/S0006-2952(02)01255-8 12167492
20. Etievant C Kruczynski A Barret JM Tait AS Kavallaris M Hill BT Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro Cancer Chemother Pharmacol 2001, 48:62-70. 10.1007/ s002800100275 11488526
21. Kim TY Yang SH Lee SH Park YS Im YH Kang WK Ha SH Park CI Heo DS Bang YJ Kim NK A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer Am J Clin Oncol Cancer Clin Trials 2002, 25:238-243.
22. Pignon JP Bourhis J Domenge C Designe L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data Lancet 2000, 355:949-955. 10768432
23. Geh JI The use of chemoradiotherapy in oesophageal cancer Eur J Cancer 2002, 38:300-313. 10.1016/S0959-8049(01)00353-7 11803146
24. Rose PG Chemoradiotherapy for cervical cancer Eur J Cancer 2002, 38:270-278. 10.1016/S0959-8049(01)00352-5 11803143
25. Lukka H Hirte H Fyles A Thomas G Elit L Johnston M Fung MFK Browman G Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer - a meta-analysis Clin Oncol 2002, 14:203-212. 10.1053/ clon.2002.0076
26. Edelstein MP Wolfe LA3 Duch DS Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer Semin Oncol 1996, 23:41-47. 8610236
27. Fukuoka K Arioka H Iwamoto Y Fukumoto H Kurokawa H Ishida T Tomonari A Suzuki T Usuda J Kanzawa F Saijo N Nishio K Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells Lung Cancer 2001, 34:451-460. 10.1016/S0169-5002(01)00265-3 11714543
28. Fukuoka K Arioka H Iwamoto Y Fukumoto H Kurokawa H Ishida T Tomonari A Suzuki T Usuda J Kanzawa F Kimura H Saijo N Nishio K Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells Cancer Chemother Pharmacol 2002, 49:385-390. 10.1007/ s00280-002-0430-x 11976832
29. Erjala K Pulkkinen J Kulmala J Grenman R Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro Acta Oncol 2004, 43:169-174. 10.1080/02841860310023110 15163165
30. Simoens C Vermorken JB Korst AE Pauwels B De Pooter CM Pattyn GG Lambrechts HA Breillout F Lardon F Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro Cancer Chemother Pharmacol 2006, 58:210-218. 10.1007/ s00280-005-0147-8 16317558
31. Pauwels B Korst AEC de Pooter CMJ Pattyn GGO Lambrechts HAJ Baay MFD Lardon F Vermorken JB Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies Cancer Chemother Pharmacol 2003, 51:221-226. 12655440
32. Papazisis KT Geromichalos GD Dimitriadis KA Kortsaris AH Optimization of the sulforhodamine B colorimetric assay J Immunol Methods 1997, 208:151-158. 10.1016/S0022-1759(97)00137-3 9433470
33. Skehan P Storeng R Scudiero D Monks A McMahon J Vistica D Warren JT Bokesch H Kenney S Boyd MR New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 1990, 82:1107-1112. 10.1093/ jnci/82.13.1107 2359136
34. Vindelov LL Christensen IJ Nissen NI A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis Cytometry 1983, 3:323-327. 10.1002/cyto.990030503 6188586
35. Fertil B Dertinger H Courdi A Malaise EP Mean inactivation dose: A useful concept for intercomparison of human cell survival curves Radiation Res 1984, 99:73-84. 10.2307/3576448 6739728
36. Chou TC Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984, 22:27-55. 10.1016/0065-2571(84)90007-4 6382953
37. Leonard CE Chan DC Chou TC Kumar R Bunn PA Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck Cancer Res 1996, 56:5198-5204. 8912857
38. Gridelli C Guida C Barletta E Gatani T Fiore F Barzelloni ML Rossi A de Bellis M D'Aniello R Scognamiglio F Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: A phase I study Lung Cancer 2000, 29:131-137. 10.1016/ S0169-5002(00)00102-1 10963843
39. Semrau S Bier A Thierbach U Virchowz C Ketterer P Fietkau R Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications Strahlenther Onkol 2003, 179:823-831. 10.1007/s00066-003-1127-8 14652671
40. Delord JP Stupp R Pinel M Nguyen L Vermorken JB Phase I study of vinflunine given as a 10 minute intravenous (IV) infusion on a weekly schedule in patients (Pts) with advanced solid tumours Proc ASCO 2001, 20. (abstr. # 441)
41. Etievant C Barret JM Kruczynski A Perrin D Hill BT Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro Invest New Drugs 1998, 16:3-17. 10.1023/A:1006022811895 9740539
42. Barret JM Etievant C Hill BT In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs Cancer Chemother Pharmacol 2000, 45:471-476. 10.1007/s002800051021 10854134
43. Bonfil RD Russo DM Binda MM Delgado FM Vincenti M Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder Urol Oncol 2002, 7:159-166. 10.1016/S1078-1439(02)00184-9 12474532
44. Holwell SE Hill BT Bibby MC Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model Br J Cancer 2001, 84:290-295. 10.1054/bjoc.2000.1587 11161390
45. Kruczynski A Poli M Dossi R Chazottes E Berrichon G Ricome C Giavazzi R Hill BT Taraboletti G Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development Eur J Cancer 2006. doi:10.1016/j.ejca.2006.06.019 16973349
46. Kruczynski A Hill BT Vinflunine, the latest Vinca alkaloid in clinical development - A review of its preclinical anticancer properties Crit Rev Oncol Hematol 2001, 40:159-173. 10.1016/S1040-8428(01)00183-4 11682323
47. Hill BT Vinflunine, a second generation novel Vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers Curr Pharm Design 2001, 7:1199-1212. 10.2174/1381612013397456